Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
Humalog is used to treat diabetes. Humalog works more quickly than normal human insulin because the insulin molecule has been changed slightly.
You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood. Humalog is a substitute for your own insulin and is used to control glucose in the long term. It works very quickly and lasts a shorter time than soluble insulin (2 to 5 hours). You should normally use Humalog within 15 minutes of a meal.
Your doctor may tell you to use Humalog as well as a longer-acting insulin. Each kind of insulin comes with another patient information leaflet to tell you about it. Do not change your insulin unless your doctor tells you to. Be very careful if you do change insulin.
Humalog is suitable for use in adults and children.
Do NOT use Humalog Mix50
Warnings and precautions
Skin changes at the injection site
The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (See How to use Humalog Mix50). Contact your doctor if you are currently injecting into a lumpy area before you start injecting a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.
Other medicines and Humalog Mix50
Your insulin needs may change if you are taking
Pregnancy and breast-feeding
Are you pregnant or thinking about becoming pregnant, or are you breast-feeding? The amount of insulin you need usually falls during the first three months of pregnancy and increases for the remaining six months. If you are breast-feeding, you may need to alter your insulin intake or diet. Ask your doctor for advice.
Driving and using machines
Your ability to concentrate and react may be reduced if you have hypoglycaemia. Please keep this possible problem in mind in all situations where you might put yourself and others at risk (e.g. driving a car or operating machinery). You should contact your doctor about the advisability of driving if you have:
Dose
Preparing Humalog Mix50
Getting the pen ready to use
After injecting
Further injections
Do not mix any other insulin in a Humalog Mix50 cartridge. Once the cartridge is empty, do not use it again.
If you use more Humalog Mix50 than you should If you use more Humalog Mix50 than you need or are unsure how much you have injected, a low blood sugar may occur. Check your blood sugar.
If your blood sugar is low (mild hypoglycaemia), eat glucose tablets, sugar or drink a sugary drink. Then eat fruit, biscuits, or a sandwich, as your doctor has advised you and have some rest. This will often get you over mild hypoglycaemia or a minor insulin overdose. If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once. A glucagon injection can treat quite severe hypoglycaemia. Eat glucose or sugar after the glucagon injection. If you do not respond to glucagon, you will have to go to hospital. Ask your doctor to tell you about glucagon.
If you forget to use Humalog Mix50
If you take less Humalog Mix50 than you need or are unsure how much you have injected, a high blood sugar may occur. Check your blood sugar
If hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) is not treated they can be very serious and cause headaches, nausea, vomiting, dehydration, unconsciousness, coma or even death (see A and B in section 4 “Possible Side Effects”).
Three simple steps to avoid hypoglycaemia or hyperglycaemia are:
If you stop using Humalog Mix50.
If you take less Humalog Mix50 than you need, a high blood sugar may occur. Do not change your insulin unless your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor or pharmacist
Like all medicines, this medicine can cause side effects, although not everybody gets them. Systemic allergy is rare (≥ 1/10,000 to <1/1,000). The symptoms are as follows:
If you think you are having this sort of insulin allergy with Humalog, tell your doctor at once.
Local allergy is common (≥ 1/100 to <1/10). Some people get redness, swelling or itching around the area of the insulin injection. This usually clears up in anything from a few days to a few weeks. If this happens to you, tell your doctor.
Lipodystrophy is uncommon (≥ 1/1,000 to <1/100). If you inject insulin too often at the same place, the fatty tissue may either shrink (lipoatrophy) or thicken (lipohypertrophy). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes.
Oedema (e.g. swelling in arms, ankles; fluid retention) has been reported, particularly at the start of insulin therapy or during a change in therapy to improve control of your blood glucose.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Common problems of diabetes
A. Hypoglycaemia
Hypoglycaemia (low blood sugar) means there is not enough sugar in the blood. This can be caused if:
B. Hyperglycaemia and diabetic ketoacidosis
Hyperglycaemia (too much sugar in the blood) means that your body does not have enough insulin. Hyperglycaemia can be brought about by:
Hyperglycaemia can lead to diabetic ketoacidosis. The first symptoms come on slowly over many hours or days. The symptoms include the following:
C. Illness
If you are ill, especially if you feel sick or are sick, the amount of insulin you need may change. Even when you are not eating normally, you still need insulin. Test your urine or blood, follow your ‘sick rules’, and tell your doctor.
Before the first use store your Humalog Mix50 in a refrigerator (2°C – 8°C). Do not freeze. Keep your cartridge in use at room temperature (below 30°C) and discard after 28 days. Do not put it near heat or in the sun. Do not keep your pen or the cartridges you are using in the fridge. The pen with the inserted cartridge should not be stored with the needle attached. Keep out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month. Do not use this medicine if you notice clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance. Check each time you inject yourself. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
The active substance is insulin lispro. Insulin lispro is made in the laboratory by a ‘recombinant DNA technology’ process. It is a changed form of human insulin and so is different from other human and animal insulins. Insulin lispro is closely related to human insulin which is a natural hormone made by the pancreas. The other ingredients are protamine sulphate, m-cresol, phenol, glycerol, dibasic sodium phosphate 7H2O, zinc oxide and water for injection. Sodium hydroxide or hydrochloric acid may have been used to adjust the acidity.
Full name: Humalog Mix50 Insulin KwikPen, 100 U/ml, Suspension for injection 3ml pre-fill
- Invented name part: Humalog
- Scientific name part: insulin lispro
- Strength part: 100 U/ml
- Pharmaceutical dose form part: Suspension for injection
Name usage: English (Denmark)
Authorised dose form:
Legal status of supply: Medicinal product subject to medical prescription
Domain: Human use
Resource status: active
Product classification:
Marketing Authorisation 1 of 1
Authorisation number: EU/1/96/007/035
Region:
Marketing authorisation holder: Eli Lilly Nederland B.V.
Identifier:
Status: Active (2015-02-07T13:28:17Z)
Package 1 of 1
PMSWI: EU/1/96/007/035
Description:
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 5 Pre-filled pen (Glass type 1)
Containing:
Manufactured Item
Dose form: Suspension for injection
Unit of presentation: Pen
Ingredient
Role: Excipient
Substance: Glycerol
Ingredient
Role: Excipient
Substance: Hydrochloric acid
Ingredient
Role: Excipient
Substance: Sodium Hydroxide
Ingredient
Role: Excipient
Substance: STERILE WATER FOR INJECTION
Ingredient
Role: active
Substance: Insulin Lispro
Ingredient
Role: Excipient
Substance: Zinc Oxide
Ingredient
Role: Excipient
Substance: Metacresol
Ingredient
Role: Excipient
Substance: Trometamol
Administrable Product (1 of 1)
Dose form: Suspension for injection
Unit of presentation: Pen
Route of administration:
Ingredient
Role: Excipient
Substance: Glycerol
Ingredient
Role: Excipient
Substance: Hydrochloric acid
Ingredient
Role: Excipient
Substance: Sodium Hydroxide
Ingredient
Role: Excipient
Substance: STERILE WATER FOR INJECTION
Ingredient
Role: active
Substance: Insulin Lispro
Ingredient
Role: Excipient
Substance: Zinc Oxide
Ingredient
Role: Excipient
Substance: Metacresol
Ingredient
Role: Excipient
Substance: Trometamol